NGL Fine Chem Q3 FY26: Revenue ₹127.51 Cr, PAT ₹15.69 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹128Cr
- +43.8% YoY
- +6.7% QoQ
- Net profit
- ₹16Cr
- +1500% YoY
- +60% QoQ
- Margin
- 18%
- +12 pp YoY
- +4 pp QoQ
Guidance rank: #36 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on NGL Fine Chem Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Quarterly Revenue (Q3FY26): ₹127.51 crores. EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY.
From NGL Fine Chem Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Quarterly Revenue (Q3FY26): ₹127.51 crores
- Year-on-Year (Y-o-Y) Revenue Growth: 43.11%
- Quarterly Revenue (Q3FY25): ₹89.10 crores
- Revenue from Operations growth (9MFY26 vs 9MFY25): 28.74% (₹351.89 crores vs ₹273.34 crores)
- Volume drivers: Growth driven primarily by higher volumes across the product portfolio, with price realizations broadly stable (Management commentary on Page 6)
2 more points from NGL Fine Chem Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what NGL Fine Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Greenfield Expansion at Tarapur
- Larger capacity expansion to drive next growth leg
- Estimated capex ₹160 crore
- Funded through debt and internal accrual
- Civil construction underway
- Invested ₹156 crore till Q3FY26
- Phase II commissioning scheduled for Q1FY27
- Commercial production expected from H2 FY27 after trial and validation batches
- Total revised investment approx. ₹210 crore
- Subsidiary Macrotech Expansion
- Completed expansion with additional intermediate capacities
- Commercial production started
- Funding
- Borrowings capped at approx. ₹85 crore
- Remaining funding from internal accruals
2 more points from NGL Fine Chem Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what NGL Fine Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
NGL Fine Chem Ltd — Quarterly revenue & net profit
NGL Fine Chem Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 128 | 89 | +43.8% | 120 | +6.7% |
| Operating profit (EBITDA) | 22 | 5 | +340% | 17 | +29.4% |
| Operating margin | 18% | 6% | +12 pp | 14% | +4 pp |
| Profit before tax | 21 | 1 | +2000% | 13 | +61.5% |
| Net profit (PAT) | 16 | 1 | +1500% | 10 | +60% |
| EPS (₹) | 25.40 | 2.07 | +1127.1% | 15.59 | +62.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹159 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What NGL Fine Chem's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
NGL Fine Chem Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were NGL Fine Chem Ltd Q3 FY26 results?
Quarterly Revenue (Q3FY26): ₹127.51 crores. EBITDA for Q3FY26: ₹22.31 crores, up 338% YoY.
What is NGL Fine Chem Ltd share price analysis?
NGL Fine Chem Ltd currently shows a neutral. The stock trades at a P/E of 33.9 with a market cap of ₹1,711 Cr. Investors should review the full earnings analysis for detailed insights.
Is NGL Fine Chem Ltd planning capital expenditure?
Greenfield Expansion at Tarapur - Larger capacity expansion to drive next growth leg - Estimated capex ₹160 crore - Funded through debt and internal accrual - Civil construction underway - Invested ₹156 crore till Q3FY26 - Phase II commissioning scheduled for Q1FY27 - Commercial production expected from H2 FY27 after trial and validation batches - Total revised investment approx.
Keep NGL Fine Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
